Floatz logo

Azacitidine

Hematopoietic And Lymphoid System Neoplasm

Explore 134 assets in Hematopoietic And Lymphoid System Neoplasm →
Floatz Rating
B58/100
Confidence
Indicative
v0.2
Sponsor
Jacqueline Garcia, MD
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07148180CT.gov
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
—Recruiting———
NCT04588922CT.gov
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
—Recruiting———
NCT05175508CT.gov
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
—Unknown———
NCT04068597CT.gov
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
—Recruiting———
NCT03471260CT.gov
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
—Recruiting———
NCT00741234CT.gov
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Hematopoietic And Lymphoid System Neoplasm

AssetSponsorPhaseRating
Azacitidine (this asset)Jacqueline Garcia, MDP2/3B · 58
AdriamycinOHSU Knight Cancer InstituteP4BBB
DexasoneCity of Hope Medical CenterP3BB
TeclistamabJanssen Pharmaceutical K.K.P2BB
CyclophosphamideNational Cancer Institute (NCI)P3BB
Allogeneic, Ex Vivo Expanded, Umbilical Cord Blood-Derived Hematopoietic Cd133+ Progenitor Cells- Cultured Fraction (Cf)Gamida Cell ltdP3BB
BortezomibOHSU Knight Cancer InstituteP4BB
EtoposideCiusss de L'Est de l'Île de MontréalP2BB
PembrolizumabVividion Therapeutics, Inc.P3BB

+42 more in the Hematopoietic And Lymphoid System Neoplasm cohort

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Azacitidine in Hematopoietic And Lymphoid System Neoplasm. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/azacitidine-hematopoietic-and-lymphoid-system-neoplasm

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →